     AV-412AVEO has acquired from Mitsubishi Pharma Corporation an exclusive license to develop and commercialize Mitsubishi's novel dual kinase inhibitor, AV-412, in all territories outside of Asia. AV-412 is an IND-ready, second-generation, oral EGFR/HER2 inhibitor that could potentially treat patients with solid tumors. It has shown excellent activity in various xenograft models and has a toxicity profile similar to other molecules in its class. Notably, in preclinical models, AV-412 is active against tumor cells that are resistant to first-generation kinase inhibitors. AV-412's mechanism of action has the potential to benefit patients with Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreatic Cancer, Head & Neck Cancer and Hormone Refractory Prostate Cancer. AVEO's in vivo cancer models offer an opportunity to exploit AV-412's unique characteristics and will provide further insight into potential clinical settings, tumor subtypes and responsive patient populations. AV-412 Phase I clinical trials were initiated in October, 2006. For more information on the trial, visit www.clinicaltrials.gov and search AV-412. Alternatively, click here. |
|
 |
|
